Add BrightSurf on Google Email

Dartmouth Health


Comparing cancer drug effectiveness from cells to mice to man

A new study by Dartmouth researchers has precisely determined the mechanism of cancer drug gemcitabine in human patients, enabling more effective combination therapies and rational clinical trial design. The research bridged the gap between experimental models and human trials, providing valuable insights into the drug's effects on cel...

SourceDartmouth Health·JournalOncoTargets and Therapy·DateSep 6, 2017

Drug combination shows better tolerance and effectiveness in metastatic renal cell cancer

A new study found that the combination of nivolumab and ipilimumab therapy demonstrates manageable safety, notable antitumor activity, and durable responses with promising long-term overall survival in patients with metastatic renal cell cancer. The treatment shows enhanced antitumor activity compared to monotherapy in tumor types such...

SourceDartmouth Health·JournalJournal of Clinical Oncology·DateJul 26, 2017

Shooting the Achilles heel of nervous system cancers

Researchers at Dartmouth's Norris Cotton Cancer Center have discovered a novel synthetic lethality screen to discover molecules that target genetically modified yeast lacking NF1. The team identified one lead candidate called Y100, which disrupts tumor cell growth and induces oxidative stress causing death of NF1-deficient cancer cells.

SourceDartmouth Health·JournalOncoTargets and Therapy·DateJul 20, 2017

E-cigarettes increase risk of cigarette smoking in youth

A systematic review and meta-analysis of published studies found strong evidence that e-cigarette use increases the risk of subsequent cigarette smoking among adolescents and young adults. E-cigarettes may mimic smoking behavior through similar hand-to-mouth movements and contain nicotine, potentially enhancing addiction.

SourceDartmouth Health·JournalJAMA Pediatrics·DateJun 28, 2017

Immunity against melanoma is only skin deep

A new study by Dartmouth researchers reveals that resident memory T cells reside in the skin, where they can quickly eliminate melanoma cells. This finding suggests that these immune cells play a crucial role in protecting against future tumors and may serve as a target for future cancer therapies.

SourceDartmouth Health·JournalScience Immunology·DateApr 14, 2017

Market and demographic factors in forming ACOs

Researchers at The Dartmouth Institute for Health Policy & Clinical Practice found that more than half the US population lives in areas where ACOs have been established. These areas tend to have higher performance on quality measures, greater managed care penetration and lower poverty rates.

SourceDartmouth Health·JournalHealth Services Research·DateOct 8, 2013

TV drug ads: The whole truth?

Researchers found that six out of ten claims made by TV drug ads are potentially misleading, leaving out important information or exaggerating benefits. The study analyzed advertisements for prescription and over-the-counter drugs aired between 2008 and 2010 and found that most claims were either false or misleading.

SourceDartmouth Health·JournalJournal of General Internal Medicine·DateSep 16, 2013

New probe provides vital assist in brain cancer surgery

A new probe developed at Norris Cotton Cancer Center and Dartmouth College helps surgeons differentiate between cancerous tissue and normal tissue in low-grade tumors. The probe reads how light travels through tissue, producing a straightforward answer as to whether the tissue is cancerous.

SourceDartmouth Health·JournalJournal of Biomedical Optics·DateJul 24, 2012

Quality variations exist, even among leading health systems

A study of nearly 11,000 total knee replacements across five top health systems revealed significant variations in length of stay, operating room time, and in-hospital complications. The data showed that surgeons with higher volumes tend to have shorter procedures, while older and sicker patients had longer hospital stays.

SourceDartmouth Health·JournalHealth Affairs·DateMay 10, 2012

Dartmouth study uses the patient's tumor to form vaccine

A new dendritic cell vaccine has been developed at Dartmouth Health, which uses the patient's own tumor cells to stimulate an anti-tumor response. The study found that over 60% of patients who received the vaccine developed immune responses against their tumors, with a significant survival rate five years after treatment.

SourceDartmouth Health·JournalClinical Cancer Research·DateNov 24, 2010